Memantinas

Memantine is an adamantane derivative and NMDA receptor antagonist primarily prescribed for the management of moderate-to-severe Alzheimer's disease. It works by blocking glutamate-mediated neuronal excitotoxicity, distinguishing it mechanistically from the cholinesterase inhibitors typically used in Alzheimer's treatment. At supratherapeutic doses, memantine can produce prolonged dissociative effects reportedly lasting 16 or more hours, placing it among the longest-duration dissociatives available.

Also known as: Dmaa, Ebixa, Axura, D-145, Memaxa, Namenda, Akatinol, Memantinum, Memantina, DRG-0267, Dimethylamylamine, 1,3-DMAA, Methylhexanamine

Classification

Chemical: Medicine
Psychoactive: Dissociative
Psychoactive: Nootropic
Psychoactive: Stimulant
Tag: adamantane
Tag: Adamantane derivative
Tag: Habit-Forming
Tag: Pharmaceutical
Tag: Research-Chemical
Tag: Tentative

Effects

Sedation
Stimulation
Incoordination
Nausea
Insomnia
Bodily Buzzing
Confusion
Anxiety
Dissociation
Memory Suppression
Dizziness
Motor Control Loss
Hallucinations
Open Eye Visuals
Visual Trails
Closed Eye Visuals
Double Vision
Increased Libido

Routes of Administration

Oral

Dosage

Heavy: 40-80 mg
Light: 10 – 30 mg
Common: 30 – 50 mg
Strong: 50 – 80 mg
Threshold: 5-10 mg

Duration

Onset: 0.5-1.5 h
Comeup: 2-3 h
Peak: 3-12 h
Offset: 5-24 h
After Effects: 24-72 h
Total Duration: 8-24 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu